Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Event Logistics

- PMLiVE

Allergies and asthma

Reframing the conversation from disease burden to prevention and health promotion

Products as portfolios: positioning immuno-oncology products

The last few years have seen a huge proliferation in the number of products entering the oncology space, with a lot more currently being investigated in clinical trials. Effective positioning...

Blue Latitude Health

- PMLiVE

Merck & Co gets EU green light for hep C drug Zepatier

Will enter a market currently dominated by Gilead's Harvoni and Sovaldi

- PMLiVE

NICE swayed by extra data on Amgen’s Imlygic

Cost effectiveness watchdog backs immunotherapy in final draft guidance

AstraZeneca AZ global R&D corporate HQ

AZ’s selumetinib stumbles at last fence in lung cancer

Phase III trial shows failure to improve patient survival rates

- PMLiVE

Sigma-Tau Pharmaceuticals appoints CEO

Interim CEO Michael Minarich takes up the post in a permanent capacity

- PMLiVE

Is your multichannel having the desired impact on both your customer and business?

The critical role of multichannel in delivering a differentiated customer experience and tangible business results

Astellas launches digital health investment company

Will look for firms that focus on patient outcomes and offer pharma synergies

Sanofi reception

EC approves Sanofi’s deal for Boehringer’s consumer business

Regulator passes the acquisition, subject to the French firm divesting some products

- PMLiVE

EMA says adaptive pathways programme still needs refinement

Scheme aims to accelerate patient access to new drugs

Making a difference together

It was highlighted at the 2016 World Economic Forum that ‘good business’ now means more than financial success, with multiple stakeholders asking how business will benefit society. At Lucid, our...

Lucid Group Communications Limited

Bristol-Myers Squibb (BMS) building

BMS rocked by Opdivo failure in lung cancer

PD-1 inhibitor phase III trial reveals disappointing results

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links